BRC
SALT LAKE CITY, UT · Other · 50 employees
BRC is a pharmaceutical manufacturing firm focused on the production of DEA approved cannabinoid API for researchers & drug developers across the United States. Our mission is to provide federally compliant, active pharmaceutical ingredients for plant-based therapeutics, with uncompromising quality, for patients and researchers everywhere.
Funding history
- Funding Round — $35.0M — Jul 2025
- Series series a — $20.0M — Oct 2022
- Funding Round — $256.0M — Apr 2022
- Funding Round — $169.8M — Mar 2022
- Funding Round — $169.8M — Mar 2022
Recent signals
- Nov 03, 2025: SEC 8-K (2.02): On November 3, 2025, BRC Inc. announced its financial results for the quarter ended September 30, 2025, detailing key performance metrics and issuing financial guidance for the full year of fiscal 2025. This announcement highlights the company's performance over the recent quarter and provides insights into anticipated future financial outcomes. The press release, which is furnished as Exhibit 99.1, includes numerical metrics and comparative analysis to previous periods, crucial for investors monitoring the company's growth and market position. The report is pivotal for stakeholders assessing the overall financial health and projected performance of BRC Inc.
- Jul 17, 2025: Raised $35.0M
- Oct 04, 2022: Raised $20.0M in Series series a
- Apr 19, 2022: Raised $256.0M
- Mar 29, 2022: Raised $169.8M
- Mar 29, 2022: Raised $169.8M
- Feb 24, 2022: Raised $1.4B
See plans & pricing → Track BRC’s funding, hiring, and signals — with verified contacts — on Fundz.